tbuckley/cabot-search huggingface dataset:
Evaluating Industry Payments Among Dermatology Clinical Practice Guidelines Authors
Authors: Jake X. Checketts, Matthew Thomas Sims, Matt Vassar
Journal: JAMA Dermatology (2017)

It is well documented that financial conflicts of interest influence medical research and clinical practice. Prior to the Open Payments provisions of the Affordable Care Act, financial ties became apparent only through self-disclosure. The nature of financial interests has not been studied among physicians who develop dermatology clinical practice guidelines.To evaluate payments received by physicians who author dermatology clinical practice guidelines, compare disclosure statements for accuracy, determine whether pharmaceutical companies from which the authors received payments manufactured products related to the guidelines, and examine the extent to which the American Academy of Dermatology enforced their Administrative Regulations for guideline development.Three American Academy of Dermatology guidelines published from 2013 to 2016 were retrieved. Double data extraction was used to record financial payments received by 49 guideline authors using the Open Payments database. Payments received by the authors from the date of the initial literature search to the date of publication were used to evaluate disclosure statement accuracy, detail the companies providing payments, and evaluate Administrative Regulations enforcement. This study is applicable to clinical practice guideline panels drafting recommendations, physicians using clinical practice guidelines to inform patient care, and those establishing policies for guideline development.Our main outcomes are the monetary values and types of payments received by physicians who author dermatology guidelines and the accuracy of disclosure statements. Data were collected from the Open Payments database and analyzed descriptively.Of the 49 authors evaluated, 40 received at least 1 reported industry payment, 31 accepted more than $1000, 25 accepted more than $10 000, and 18 accepted more than $50 000. Financial payments amounted to a mean of $157 177 per author. The total reimbursement among the 49 authors from 2013 to 2015 was $7 701 681. Of the 40 authors receiving payments, 22 did not accurately disclose industry relationships. Authors received payments from companies with products directly related to the guideline topic. Violations to the Administrative Regulations were found.Dermatology clinical practice guideline authors received sizable industry payments and did not completely disclose these payments. The American Academy of Dermatology policies may benefit from stricter enforcement or the adoption of new standards.
The role of the microbiome in psoriasis: moving from disease description to treatment selection?
Authors: E.A. Langan, C.E.M. Griffiths, W. Solbach, J.K. Knobloch, D. Zillikens, D. Thaçi
Journal: British Journal of Dermatology (2017)

With several million microbes per square centimetre of skin, the task of mapping the physiological cutaneous microbiome is enormous. Indeed, the reliance on bacterial culture to identify cutaneous bacterial communities has led to a systematic underappreciation of cutaneous microbial diversity, potentially limiting our understanding of common inflammatory skin diseases, including psoriasis. However, based heavily on developments in molecular biology and bioinformatics, including next-generation sequencing, the last decade has witnessed a marked increase in our understanding of the extent and composition of the cutaneous microbiome. It is already clear that skin-specific (skin site and skin microenvironment), individual-specific (hygiene, sex, age and hormonal status), disease-specific (atopic eczema, acne) and genetic factors can all influence the cutaneous microbiome, albeit to varying and, as yet, ill-defined extents.To investigate the role of the microbiome in psoriasis and to outline how microbiome studies can be harnessed to provide new insights into disease pathogenesis and treatment selection.This review briefly describes the process of 16S ribosomal RNA sequencing and then charts our current understanding of the cutaneous microbiome in health and the alterations (dysbiosis) associated with chronic inflammatory diseases, with particular reference to psoriasis.The possibility and clinical relevance of intraindividual cross-talk between the various microbiomes is discussed and potential mechanisms underpinning the interactions between resident skin flora and the immune system are highlighted.Ultimately, in the age of personalized medicine, the integration of cutaneous microbiome signatures and comprehensive disease and drug response endotypes will herald a novel approach in the clinical management of chronic multisystem inflammatory diseases.
3A.01 Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti- PD-1 Therapy in Advanced Lung Cancer: A Retrospective Analysis
Authors: A. Hegde, C. Cherry, G. Stroud, R. Pinnamaneni, S. Cherukuri, M. Bowling, H. Arastu, P.R. Walker
Journal: Journal of Thoracic Oncology (2017)
TCT-790 Long-term follow-up after transcatheter aortic valve implantation and durability of transcatheter aortic valves - results of a prospective single-center registry
Authors: Stephan Haussig, Constantin Pleissner, Marion Zimmer, Norman Mangner, Felix Woitek, Georg Stachel, Philipp Kiefer, David Michael Holzhey, Sergey Leontyev, Friedrich-Wilhelm Mohr, Gerhard Schuler, Axel Linke
Journal: Journal of the American College of Cardiology (2017)
Actr Platform As an Adaptable, Universal T Cell Therapy That Can Target Multiple Tumor Antigens to Overcome Antigen Escape
Authors: Greg Motz, Eugene Choi, Tooba Cheema, Taylor Friedman, Taylor Hickman, Allison Nelson, John Shin, Ryan Boomer, James Hemphill, Kathleen McGinness, Heather A Huet, Seth A Ettenberg
Journal: Blood (2016)
Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy
Authors: Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana, Ulka Vaishampayan
Journal: Journal for ImmunoTherapy of Cancer (2017)

There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocyte ratio (NLR) and duration of prior anti-vascular endothelial growth factor (VEGF) inhibitors, as predictors of response rate, progression free survival (PFS) and overall survival (OS) in mRCC patients treated with immune checkpoint inhibitor (ICI).Regulatory approval was obtained. A single center retrospective chart review of mRCC patients at Karmanos Cancer Institute, treated with ICI based therapy (PD-1/PD-L1 inhibitors) was conducted. Data were collected on demographics, smoking status, prognostic scoring (Memorial Sloan Kettering and Heng criteria), NLR pretherapy, post 1 and 4 doses of ICI, and duration of prior anti-VEGF therapy ≥6 months or <6.42 patients were evaluated with median age of 61 years (range, 24-85). Pretherapy NLR < 3 and ≥3 was seen in 19 (45%) and 23 (55%) patients, respectively. 24 (57%) and 18 (43%) patients had prior anti-VEGF inhibitors for a duration of ≥6 months and <6 months, respectively. 12 (29%), 22 (52%) and 8 (19%) patients had favorable, intermediate and poor risk disease based on Heng criteria, respectively. Multivariable analysis showed pretherapy NLR ≥3 was predictive of shorter PFS and OS when treated with ICI with median 3.08 months and 13.50 months, respectively, versus 15.57 months and not reached for NLR < 3 (adjusted p-values =0.003 and 0.025, respectively). Prior anti-VEGF therapy <6 months was predictive of increased likelihood of benefit from ICI therapies (adjusted p = 0.028). The median PFS was 3.72 months and 14.33 months, respectively, in cases with prior anti-VEGF therapy for ≥6 months and <6 months.Pretherapy NLR <3 and duration of prior anti-VEGF therapy of <6 months, are independent statistically significant predictors of longer PFS and OS with ICI therapy in mRCC. Validation is required in a larger sample size with multi-institutional collaboration.
Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324.
Authors: Sonja Loges, Isabel Ben Batalla, Michael Heuser, Nikolas Berenbrok, Thomas Schroeder, Stefanie Geyh, David Micklem, Jörg Chromik, Maxim Kebenko, Walter M. Fiedler, Murray Yule, Jorge E. Cortes, Bjorn T. Gjertsen
Journal: Journal of Clinical Oncology (2017)

7059 Background: The interplay with bone marrow stroma plays an important role in the pathobiology of MDS. Gas6 is secreted by mesenchymal bone marrow stroma cells and promotes survival and therapy resistance of AML cells expressing the Axl receptor. We hypothesized that inhibiting Axl by the small molecule inhibitor BGB324 might hold therapeutic potential in MDS. Methods: We investigated the inhibitory effect of BGB324 on primary bone marrow mononucleated cells (BMMNC) and mesenchymal stroma cells (MSC) from MDS patients in comparison to healthy donors. In the ongoing first-in-patient Phase 1a/b trial BGBC003 A standard 3 + 3 dose escalation study was performed to identify the maximum tolerated dose of BGB324 in patients with previously treated high risk MDS or AML. BGB324 was administered as an oral loading dose on days one and two followed by a reduced daily maintenance. Three dose levels were explored 400/100mg, 600/200mg and 900/300mg. Results: We found that BGB324 inhibited BMMNC from low- and high-risk MDS patients with an IC50 of 2.1 µM and 3.8 µM, respectively (n = 5). In comparison, BMNNC from healthy donors were resistant to BGB324 (IC50 9.4 µM, p &lt; 0.05, n = 10). Axl expression was present in MSC isolated from the BM of MDS patients and BGB324 inhibited the proliferation of MSC from low- and high-risk MDS patients (IC50 2.5 µM and 2.7 µM, respectively; n = 7/5).To date, 3 patients with MDS were treated with 400 mg loading dose and 100 mg maintenance dose of BGB324. Therapy has been well-tolerated and the MTD has not yet been reached. The majority of adverse events reported have been Grade 1 and 2. The most common related adverse events are diarrhea and fatigue. One patient with MDS was treated for 80 weeks and experienced a PR. Evidence of target inhibition was demonstrated by almost complete inhibition of Axl phosphorylation accompanied by reduction in phosphoErk and phosphoAkt signalling at day 21 of treatment. Conclusions: BGB324 is well-tolerated and might represent a promising novel treatment approach in MDS. Safety and efficacy of BGB324 will be explored further in clinical trials. Clinical trial information: NCT02488408.
P1.05-063 Multicenter Observational Study of Patients with Resected Early-Staged NSCLC, Who Were Excluded from an Adjuvant Chemotherapy Trial
Authors: Tomoyuki Hishida, Masahiro Tsuboi, Kiyotaka Yoh, Kazuya Takamochi, Hiroyuki Sakurai, Yasushi Goto, Takehiro Shukuya, Yasuo Ohashi, Hideo Kunitoh
Journal: Journal of Thoracic Oncology (2017)
TCT-296 Impact of Baseline Positive Coronary Artery Remodeling on 2-year Outcomes after IVUS-guided PCI: The ADAPT-DES IVUS Sub-Study
Authors: Song-Yi Kim, Gary Mintz, Bernhard Witzenbichler, Michael Rinaldi, Ernest Mazzaferri, Peter L. Duffy, Bruce Brodie, Yangbo Liu, Ajay Jayant Kirtane, Gregg Stone, Akiko Maehara
Journal: Journal of the American College of Cardiology (2017)
Using Epidemiology to Determine Surgical Needs in Low-Resource Settings
Authors: Joseph D. Forrester, Sherry M. Wren
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma
Authors: Kefeng Wang, Wei Jin, Yan Song, Xiang Fei
Journal: Molecular Cancer (2017)

Accumulating evidence indicates that long non-coding RNAs (lncRNAs) play a crucial role in tumorigenesis. Here, we report a novel lncRNA, RP11-436H11.5, that regulates renal cell carcinoma (RCC) cell proliferation and invasion by sponging miR-335-5p. Expression of lncRNA RP11-436H11.5 was determined by a qRT-PCR assay in RCC tissues. RCC cell proliferation and invasion were measured by a cell proliferation assay and a transwell invasion assay. Expression of BCL-W was detected by a western blot assay. Interactions between lncRNA RP11-436H11.5 and miR-335-5p were measured by a luciferase reporter assay and a RNA-pull down assay. In vivo experiments were used to detect tumor formation. In this study, the qRT-PCR results illustrated that lncRNA RP11-436H11.5 was more highly expressed in RCC tissues than in adjacent normal renal tissues. The results of survival analysis indicated that patients in the high lncRNA RP11-436H11.5 group presented significantly worse outcomes compared with those in the low lncRNA RP11-436H11.5 group. Downregulation of lncRNA RP11-436H11.5 suppressed RCC cell proliferation and invasion in vitro and in vivo. Luciferase reporter assay results demonstrated that lncRNA RP11-436H11.5 enhanced BCL-W expression by regulating miR-335-5p expression. LncRNA RP11-436H11.5 could function as a miR-335-5p decoy to derepress expression of BCL-W. LncRNA RP11-436H11.5 could function as a competing endogenous RNA to promote RCC cell proliferation and invasion, which might serve as a therapeutic application to suppress RCC progression.
Abstract 16641: 68Ga-DOTATATE PET Outperforms 18F-FDG PET for Imaging Vascular Inflammation in Atherosclerosis
Authors: Jason M Tarkin, Francis R Joshi, Nicholas R Evans, Mohammed M Chowdhury, Nichola L Figg, Aarti V Shah, Lakshi T Starks, Roie Manavaki, Abel Martin-Garrido, Emma Yu, Rhoda E Kuc, Luigi Grassi, Roman Kreuzhuber, Myrto Kostadima, Mattia Frontini, Willem H Ouwehand, Ashley M Groves, Deepa Gopalan, Peter J Kirkpatrick, Patrick A Coughlin, John R Buscombe, Tim D Fryer, Martin R Bennett, Elizabeth A Warburton, Anthony P Davenport, James H Rudd
Journal: Circulation (2016)

Introduction: Activated macrophages express somatostatin receptor subtype-2 (SST2) within unstable and high-risk atherosclerotic plaques. Hypothesis: We tested the hypothesis that 68Ga-DOTATATE, a ...
SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part III: Pulmonic Valve
Authors: Ziyad M. Hijazi, Carlos E. Ruiz, Evan Zahn, Richard Ringel, Gabriel S. Aldea, Emile A. Bacha, Joseph Bavaria, R. Morton Bolman, Duke E. Cameron, Larry S. Dean, Ted Feldman, David Fullerton, Eric Horlick, Michael J. Mack, D. Craig Miller, Marc R. Moon, Debabrata Mukherjee, Alfredo Trento, Carl L. Tommaso
Journal: Journal of the American College of Cardiology (2015)
Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling
Authors: Kumar Dharmarajan, Robert L. McNamara, Yongfei Wang, Frederick A. Masoudi, Joseph S. Ross, Erica E. Spatz, Nihar R. Desai, James A. de Lemos, Gregg C. Fonarow, Paul A. Heidenreich, Deepak L. Bhatt, Susannah M. Bernheim, Lara E. Slattery, Yosef M. Khan, Jeptha P. Curtis
Journal: Annals of Internal Medicine (2017)

Publicly reported hospital risk-standardized mortality rates (RSMRs) for acute myocardial infarction (AMI) are calculated for Medicare beneficiaries. Outcomes for older patients with AMI may not reflect general outcomes.To examine the relationship between hospital 30-day RSMRs for older patients (aged ≥65 years) and those for younger patients (aged 18 to 64 years) and all patients (aged ≥18 years) with AMI.Retrospective cohort study.986 hospitals in the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines.Adults hospitalized for AMI from 1 October 2010 to 30 September 2014.Hospital 30-day RSMRs were calculated for older, younger, and all patients using an electronic health record measure of AMI mortality endorsed by the National Quality Forum. Hospitals were ranked by their 30-day RSMRs for these 3 age groups, and agreement in rankings was plotted. The correlation in hospital AMI achievement scores for each age group was also calculated using the Hospital Value-Based Purchasing (HVBP) Program method computed with the electronic health record measure.267 763 and 276 031 AMI hospitalizations among older and younger patients, respectively, were identified. Median hospital 30-day RSMRs were 9.4%, 3.0%, and 6.2% for older, younger, and all patients, respectively. Most top- and bottom-performing hospitals for older patients were neither top nor bottom performers for younger patients. In contrast, most top and bottom performers for older patients were also top and bottom performers for all patients. Similarly, HVBP achievement scores for older patients correlated weakly with those for younger patients (R = 0.30) and strongly with those for all patients (R = 0.92).Minority of U.S. hospitals.Hospital mortality rankings for older patients with AMI inconsistently reflect rankings for younger patients. Incorporation of younger patients into assessment of hospital outcomes would permit further examination of the presence and effect of age-related quality differences.American College of Cardiology.
TCT-713 Comparison of Single Cutoff Instantaneous Wave-Free Ratio versus Hybrid Protocol using Fractional Flow Reserve on Intermediate Coronary Lesions: Results from a Single-center Registry
Authors: Shunsuke Aoi, Yumiko Kanei, Bora Toklu, Neil Patel, Wonkyoung Lee, John Fox
Journal: Journal of the American College of Cardiology (2017)
Sífilis e infecção gonocócica na República Checa
Authors: H Zákoucká, V Polanecký, V Kaštánková
Journal: Eurosurveillance (2004)

A sifilis continua sendo um problema de saude publica na Republica Checa, como em todas as partes do mundo. A Republica Checa, que formava parte da Checoslovaquia ate 1993, tem desde muito tempo uma tradicao de saude publica e a vigilância das IST esta principalmente centrada nas infeccoes chamadas ‘doencas venereas’ : a sifilis, a infeccao gonococica, o cancro mole e o linfogranuloma venereo. As campanhas de prevencao desde o inicio dos anos 50 consigueram controlar a sifilis e a infeccao gonococica ; o cancro mole e o linfogranuloma venereo sao doencas muito raras. Ao final dos anos 80, a incidencia de novos casos de sifilis era baixa (100-200 casos anuais), entretanto que no mesmo periodo eram registrados 6 500 casos de infeccao gonococica por ano. Na Republica Checa, os cuidados de saude e a prevencao das IST estao basados em uma cooperacao estreita entre as unidades clinicas e os servicos microbiologicos e epidemiologicos dos Servicos de saude ambiental. A partir de 1959 existem estatisticas anuais sobre os casos notificados de ‘doencas venereas’, seguindo os codigos da Classificacao internacional das doencas, 10a revisao (ICD-10). Nao ha dados estatisticos desagregados sobre outras IST. So estao disponiveis desde 2000 dados agregados de infeccoes por Chlamydia trachomatis [5]. Depois da transformacao politica e social de 1989 na communidade Checa, produziu-se um claro aumento da sifilis. Uma proporcao de 50% a 60% dos casos notificados foram classificados como latentes tardios ou de duracao desconhecida. A persistencia de casos de sifilis congenita (7 a 18 casos anuais) durante os anos 90 tambem representa um fenomeno que nao deve ser ignorado. Os casos estavam concentrados em grandes areas urbanas com um nivel importante de prostituicao. Tambem se identificou uma proporcao alta de casos em refugiados. Entanto a incidencia anual da infeccao gonococica baixava progressivamente entre 1994 e 2001 (de 28,5 a 8,9 casos por 100.000) a incidencia da sifilis aumentou durante o mesmo periodo de 3,6 a 9,6 por 100.000 (com um maximo de 13,4 em 2001), sobrepassando en 2000, pela primeira vez desde muitos anos, a incidencia da infeccao gonococica.
Subcellular Localization of Survivin Determines Its Function in Cardiomyocytes
Authors: Tien-Jui Tsang, Ying-Chang Hsueh, Erika I Wei, David J Lundy, Bill Cheng, You-Tzung Chen, Shoei-Shen Wang, Patrick C H Hsieh
Journal: Theranostics (2017)

Rationale: Reducing cardiomyocyte death and enhancing their proliferation after myocardial infarction is perhaps the single largest challenge for cardiac tissue regeneration. Survivin (SVV) is the smallest member of the inhibitor of apoptosis (IAP) family but plays two important roles; inhibiting caspase-9 activation in the intrinsic apoptosis pathway, and regulating microtubule dynamics and chromosome segregation during cell division. Genetic depletion of cardiac SVV leads to incomplete cardiomyocyte division and abnormal heart development. However, the function of SVV in adult hearts after myocardial infarction remains unclear. Methods: A homozygous inducible cardiomyocyte-specific SVV knockout transgenic mouse model was established through crossbreeding SVVflox/flox and αMHC-MCM transgenic mice. Adult mice received consecutive intraperitoneal injection of tamoxifen to induce genetic removal of SVV in cardiomyocytes. A SVV overexpressing model was established via local delivery of SVV in wild-type mouse hearts. Results: We found that 30.82% of cardiomyocytes in the peri-infarct region of SVV knockout mice were apoptotic, significantly higher than the 22.18% in control mice. In addition, ejection fraction was 29.00±0.40% in knockout mice compared to 38.04±0.50% in control mice 21 days after myocardial infarction. On the contrary, locally overexpressing SVV in the heart improved cardiac functions. Unexpectedly, we found that altering the subcellular localization of SVV overexpression produced different outcomes. Overexpression of SVV in the cytoplasm decreased cardiomyocyte apoptosis, whereas overexpression of SVV in the nucleus enhanced cardiac regeneration. The ejection fraction of mice overexpressing SVV was 36.58±0.91%, significantly higher than 28.18±1.70% in the GFP control group. Apoptotic cardiomyocytes were only 4.63% in mouse overexpressing cytosolic SVV, compared to 9.31% in the GFP group, and activation of caspase-3 was also reduced. Moreover, mice overexpressing NLS-SVV exhibited a better ejection fraction (36.19±1.02%,) than GFP controls (26.69±0.75%). NLS-SVV enhanced H3P-positive cardiomyocytes in the border zone to 0.28%, compared to only 0.08% in GFP group, through interacting with Aurora B. Conclusions: We demonstrate the importance of SVV subcellular localization in regulating post-MI cardiac repair and regeneration. We hope that this will open new translational approaches through targeted delivery of SVV.
TCT-403 Impact of statin therapy on clinical outcomes after endovascular treatment in patients with femoropopliteal artery disease (from the K VIS registry data)
Authors: Wonho Kim, Young-Guk Ko, Pil-Ki Min, Jae-Hwan Lee, Cheol Woong Yu, Sang-Rok Lee, Seung Hyuk Choiu, In-Ho Chae, Donghoon Choi
Journal: Journal of the American College of Cardiology (2017)